A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Centre Oscar Lambret
Mayo Clinic
Mayo Clinic
UMC Utrecht
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
M.D. Anderson Cancer Center
Hackensack Meridian Health
UNC Lineberger Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNICANCER
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institut Bergonié
Institut Bergonié
Hadassah Medical Organization
Institut Bergonié
Institut Bergonié
University of California, San Francisco
Cedars-Sinai Medical Center
First Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University
Centre Leon Berard
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
UMC Utrecht
University Health Network, Toronto
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Grupo Espanol de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
Institut Bergonié
University of Pittsburgh
Hospital Universitario Virgen de la Arrixaca
University Hospital, Strasbourg, France
Wake Forest University Health Sciences
Ain Shams University
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Institut Bergonié
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Case Comprehensive Cancer Center
Chang Gung Memorial Hospital